Last reviewed · How we verify
NCT03058380
Stated-Preferences in Knee Arthroplasty
trial testing Stated-Preferences Evaluation Instrument in Arthritis in 348 participants. Completed in 1 June 2018.
1 June 2018
Quick facts
| Lead sponsor | Duke University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 348 |
| Start date | 17 August 2017 |
| Primary completion | 1 June 2018 |
| Estimated completion | 1 June 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Stated-Preferences Evaluation Instrument
Conditions studied
- Arthritis — all drugs for Arthritis →
- Knee Osteoarthritis — all drugs for Knee Osteoarthritis →
- Arthropathy of Knee — all drugs for Arthropathy of Knee →
Sponsor
Duke University
Who can join
Adults 40 to 80, any sex, with Arthritis or Knee Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objectives of this study are to apply best-practice stated-preference methods to quantify patient preferences for benefit-risk tradeoffs associated with arthroplasty treatment options for end-stage osteoarthritis of the knee. Duke will develop and administer stated-preference surveys to adult patients (Ages 40-80) with knee pain to collect preference data, estimate the relative importance of treatment features and outcomes, and estimate maximum acceptable risks for given benefits and minimum acceptable benefits for given harms. This study proposal describes plans for the patient stated-preference survey.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03058380
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Arthritis
Currently open trials in the same condition.
- NCT05067998 — The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature · recruiting
- NCT07284563 — Ultralow Dose PET Imaging for 18F-NaF Uptake · Phase 2 · recruiting
- NCT06915012 — Impact of Biophoton Therapy on Chronic Severe Arthritis Pain · NA · recruiting
- NCT06880653 — Dose Response of Exercise for Arthritis Management · NA · recruiting
- NCT07106931 — Early STratification of Acute ARThritis · recruiting
Other Duke University trials
Trials by the same sponsor.
- NCT07216456 — Vaginal Dilator Therapy After Pelvic Radiation · NA · not yet recruiting
- NCT07519317 — Dosing and Deployment Trial: A Home-based Optokinetic Treatment · NA · not yet recruiting
- NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
- NCT07216963 — The Community Paramedic Response and Overdose Outreach With Supportive Medical-Legal Services Study · NA · not yet recruiting
- NCT07459218 — IDEAS for Hope to Reduce Suicide Risk and Improve HIV Care Engagement in Tanzania · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03058380 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Duke University
- Last refreshed: 17 December 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03058380.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing